Nathan Ajiashvili

Partner
New York
  • 1271 Avenue of the Americas
  • New York, NY 10020
  • USA
Profile Experience

Nathan Ajiashvili, Co-Chair of the New York Corporate Department, advises companies and financial institutions on a range of public and private financings, as well as domestic and foreign entities in corporate securities matters.

Mr. Ajiashvili applies a hands-on approach to help clients successfully navigate financings at every stage of their life cycles. He offers particular experience in transactions involving the life sciences industry, including the biotech and medical device/tech spaces. His work spans dozens of initial public offerings (IPOs), including a number of dual listings involving diverse jurisdictions.

Mr. Ajiashvili complements his breadth of IPO work with various types of financing transactions, such as high yield debt offerings, public and private equity offerings, leveraged buyouts, debt exchange offers, tender offers, and consent solicitations.

A trusted strategic advisor, Mr. Ajiashvili also counsels clients on general corporate and securities matters, including corporate governance issues, public company reporting obligations, and stock exchange rules and requirements.

Mr. Ajiashvili’s representative IPO experience includes advising:

  • Precision BioSciences in connection with its IPO
  • Bank of America Merrill Lynch and JP Morgan in connection with the IPO of Avedro
  • Kiniksa Pharmaceuticals in connection with its IPO
  • Inspire Medical Systems in connection with its IPO
  • Sol-Gel Technologies in connection with its IPO
  • Bank of America Merrill Lynch in connection with the IPO of resTORbio
  • Bank of America Merrill Lynch in connection with the IPO of Spero Therapeutics
  • Verona Pharma in connection with its dual listing on the Nasdaq
  • JP Morgan and Morgan Stanley in connection with the IPO of Acushnet Holdings
  • Citigroup in connection with the IPO of Myovant Sciences
  • Merus in connection with its IPO
  • Bank of America Merrill Lynch in connection with the IPO of American Renal Associates
  • Jefferies in connection with the IPO of Aclaris Therapeutics
  • Jefferies in connection with the IPO of Axovant Sciences
  • Piper Jaffray in connection with the IPO of CoLucid Pharmaceuticals
  • Press Ganey in connection with its IPO   
  • Bank of America Merrill Lynch in connection with the IPO of Metaldyne Performance    

Mr. Ajiashvili’s representative high yield debt transactions include advising:

  • Barclays in connection with the senior notes offerings by PVH
  • The initial purchasers in connection with the senior notes offerings by Icahn Enterprises
  • Goldman Sachs in connection with the senior secured notes offerings by ContourGlobal
  • Deutsche Bank in connection with the offerings of senior secured notes and senior notes by Federal Mogul
  • Bank of America Merrill Lynch in connection with the senior notes offerings by SNF
  • Goldman Sachs in connection with the senior secured notes offering by Peabody Energy to fund its emergence from chapter 11
  • Barclays in connection with the senior notes offerings by ACCO Brands
  • Goldman Sachs in connection with the senior secured notes offering by Rivers Casino
  • Wells Fargo in connection with the senior notes offering by First Quality        
  • Credit Suisse in connection with the senior secured notes offerings by Harland Clarke
  • Bank of America Merrill Lynch in connection with the senior notes offering by Transfield Services
  • Neuberger Berman in connection with its offering of senior notes
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.